Due to the dynamic nature of HER3 expression as well as the current limitations of biopsy assessment (such as tumor heterogeneity, repeat sampling, temporal changes), a promising avenue is the molecular imaging of HER3 via Positron Emission Tomography (PET). Here, ERBB3 is linked to neoplasm.